You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The partners will leverage MedGenome's database of genetic variants in South Asians to identify and analyze genes and variants associated with Parkinson's disease.
In a newly published paper, CHOP researchers described a method for rebuilding patient histories en masse to create gene-specific "footprints" in clinical records.
The researchers proposed that increased NTRK2 regulation reduces memory formation, leading to a decreased PTSD risk among traumatized populations.
Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.
Sanford Health will help validate TruGenomix's TruGen-1 post-traumatic stress disorder test through its Imagenetics clinical genomics program.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
The test can help diagnose spinal muscular atrophy and identify carriers without symptoms who may be at risk of passing the disease to their children.
The Phase 2 grant is for work the company is doing to analyze the proteomic responses of immune cells in patients with Alzheimer's and related conditions.
The companies are applying Personalis' technology to explore immune response to genetic therapeutics in Sarepta's pipeline.
The partners aim to develop unbiased omics-based methods for identifying cases of PTSD, which may increase in the wake of the COVID-19 pandemic.
Individuals with autism spectrum disorder who were younger or with a more severe condition were more likely to undergo genetic testing, a new analysis has found.
The study also found that certain genes may influence multiple complex traits, while others only affect one phenotype, making them worthwhile therapeutic targets.
At the Biology of Genomes virtual conference last week, several presentations focused on single-cell and spatial genomics data sets and how they could be complementary.
The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
Researchers combined genome-wide association and transcriptome study data to uncover cell types affected by complex brain disorders, including Parkinson's disease.
A new analysis from a UCSD-led team has found that the mutation affecting the ACTL6B gene affects chromatin accessibility and transcription activity.
An analysis of almost 43,000 individuals under 17 years suggests polygenic scores for adult conditions such as depression may coincide with childhood psychopathology.
Invitae will provide free genetic testing on a 53-gene panel and counseling to patients suspected of having an LSD to facilitate earlier diagnosis and appropriate treatment.
Brain samples from Alzheimer's cases and controls revealed an energy metabolism-related protein network with ties to microglia and astrocyte activity.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.